A study evaluating safety of tocilizumab in Giant Cell Arteritis and Rheumatoid Arthritis patient populations.

Trial Profile

A study evaluating safety of tocilizumab in Giant Cell Arteritis and Rheumatoid Arthritis patient populations.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Giant cell arteritis; Rheumatoid arthritis
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Dec 2017 New trial record
    • 08 Nov 2017 Results of analysis assessing safety safety of tocilizumab in giant cell arteritis or rheumatoid arthritis patients from general healthcare claim database (see CTP 291318) and clinical development program presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top